Renata enters Netherlands with Parkinson’s drug

Resumen detallado
Drug maker Renata PLC has expanded its presence in Europe with the launch of Amantadine HCl capsules in the Netherlands, marking its entry into another regulated pharmaceutical…
Drug maker Renata PLC has expanded its presence in Europe with the launch of Amantadine HCl capsules in the Netherlands, marking its entry into another regulated pharmaceutical market.
According to a press release, the capsules, indicated for the symptomatic treatment of Parkinson’s disease, will be supplied from the company’s EU-GMP-approved Rajendrapur General facility in blister packs containing 56 capsules.
The product is marketed in Bangladesh by Renata under the brand name Mantadin.
With the latest launch, Renata has expanded its European presence beyond the UK, Ireland, France, Denmark, Sweden, Norway, Finland, Portugal and Cyprus, bringing its medicines to more patients across the region’s highly regulated markets, the release added.
In the first quarter of the current fiscal year, Renata’s revenue rose more than 11 percent year-on-year to Tk 1,260 crore, while its profit increased 36 percent to Tk 101 crore.
The company’s share price edged down to Tk 423 at the Dhaka Stock Exchange yesterday.
Inicio del artículo, extracto de The Daily Star. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.thedailystar.net)



